AACR, page-8

"Can anyone enlighten why this AARC will be any different from past conferences?"

Well a big difference this time is the phase 1b clinical trial data.

What we have heard from the company about the trial has been light on detail. Often when there's really great data biotechs like to release that info at large peer review conferences or publications.

It'll be interesting to see if patients are continuing to improve. As Ursula Wiedermann said in that long interview that it is hoped that B cell therapies will keep on working, as the patient keeps producing their own antibodies.

This is almost the last box we need to tick. Albeit on small data we have safety, immune response, antibodies being produced and cancers being reduced. So if the body continues to produce antibodies and they keep being effective - then that will be extraordinary good.

I can understand people doubting what imu has, especially when one looks at how low the market cap is, but clinically they have shown lots of evidence so far of having an amazing cancer treatment and platform. And it's obviously not just me that is excited, as they have attracted a who's who of names on their scientific board.

cheers